GLP-3 20mg

What is GLP-3?

GLP-3 (LY3437943) is a synthetic peptide engineered to serve as a triple-agonist, simultaneously targeting glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG) receptors. This 39-amino-acid peptide is designed for enhanced stability and pharmacokinetics through conjugation with a fatty diacid moiety, resulting in a six-day half-life. This extended half-life and robust stability make GLP-3 an exceptional tool for preclinical studies, particularly those investigating complex physiological processes such as metabolic regulation, weight management, and tissue repair. Unlike single- or dual-agonist peptides, the ability of GLP-3 to engage three receptors synergistically offers researchers a unique opportunity to explore multifaceted pathways in controlled laboratory settings.

Each 20mg vial of GLP-3 peptide is supplied as a lyophilized powder by Protide Health, ensuring stability and precise handling for longitudinal studies. To ensure accurate reconstitution and protocol development, researchers may utilize our peptide dosage calculator.

Chemical and Structural Properties of GLP-3

The design of GLP-3 is rooted in a GIP backbone, modified to amplify the biological activities of GLP-1, GIP, and glucagon, creating a versatile platform for preclinical research. Its lyophilized form ensures long-term stability when stored at -20°C or below, preventing degradation and maintaining bioactivity for extended experimental protocols. The peptide’s conjugation with a fatty diacid enhances its pharmacokinetic profile, allowing for once-weekly dosing in animal models, which is particularly advantageous for longitudinal studies requiring consistent exposure. This stability, combined with its ability to resist enzymatic degradation, distinguishes GLP-3 from other peptides that may require complex delivery systems.

• Molecular Architecture: Derived from a GIP backbone with triple-receptor agonism.

• Storage Format: Lyophilized for stability at -20°C or lower.

• Pharmacokinetics: Six-day half-life supports once-weekly dosing.

• Bioavailability: Fatty diacid conjugation enhances research viability.

Mechanisms of Action

The efficacy of GLP-3 in preclinical research stems from its ability to engage GLP-1, GIP, and glucagon receptors, producing a synergistic effect on metabolic and regenerative pathways. Its multi-receptor agonism allows it to modulate glucose homeostasis, lipid metabolism, energy expenditure, and inflammation, making it a powerful tool for studying complex physiological processes.

• GLP-1 Receptor Agonism: GLP-3 enhances glucose-dependent insulin secretion from pancreatic beta cells, reducing blood glucose levels without risking hypoglycemia. It also suppresses glucagon release, slows gastric emptying, and reduces appetite through hypothalamic and peripheral signaling. Coskun et al., 2022

• GIP Receptor Agonism: With 8.9 times greater potency than native GIP, GLP-3 amplifies insulin secretion and promotes lipid metabolism. In adipocytes, it enhances lipolysis, contributing to fat mass reduction. Preclinical rodent studies have shown significant weight loss driven by GIP-mediated appetite suppression.

• Glucagon Receptor Agonism: GLP-3 increases energy expenditure via hepatic glucose production and thermogenesis. It also reduces hepatic lipid accumulation. Sanyal et al., 2024

• Anti-Inflammatory and Tissue Repair Effects: By modulating cytokine expression, GLP-3 supports tissue regeneration in organs like the liver and kidney. Ma et al., 2024

• Neuroendocrine Regulation: Its ability to cross the blood-brain barrier enhances central effects on appetite and energy balance, supporting obesity-related neural studies.

GLP-3 Peptide Research

1. GLP-3 and Metabolic Health Models

GLP-3 achieved a 24.2% weight reduction in obese mice over 48 weeks, making it ideal for studying neuroendocrine pathways. This research helps illuminate how triple-receptor agonism affects long-term metabolic balance and energy expenditure markers. Jastreboff et al., 2023

2. Type 2 Diabetes Markers

GLP-3 reduces HbA1c and improves insulin sensitivity in diabetic rodents. These findings suggest it is an effective tool for examining how multi-receptor incretin agonists affect glucose handling, insulin sensitivity, and cardiometabolic risk markers. Rosenstock et al., 2023

3. Liver Fat and MASLD Models

GLP-3 decreases liver fat and improves histological markers in mouse models. These data make it a primary focus for labs exploring metabolic dysfunction-associated steatotic liver disease (MASLD), including biomarkers linked to steatosis and scarring. Sanyal et al., 2024

4. Cardiovascular and Renal Tissue Repair

By reducing inflammation and fibrosis, GLP-3 shows potential in diabetic kidney disease models and cardiovascular tissue studies. Researchers use it to study anti-inflammatory and angiogenic properties in organ-specific regeneration contexts. Ma et al., 2024

Research Considerations and Limitations

Conducting preclinical research with GLP-3 requires careful attention to regulatory, scientific, and ethical considerations to ensure credible and reproducible results. Its status as a research-only peptide necessitates strict adherence to laboratory protocols.

• Regulatory Compliance: Restricted to laboratory research; not approved for human consumption or therapeutic use.

• Clinical Data Status: Only preclinical and early-phase clinical data available; phase 3 trials are ongoing as of late 2023. Ray, 2023

• Dosing Precision: Subcutaneous doses require model-specific calibration for reproducibility across different experimental arms.

• Ethical Standards: Mandatory adherence to IACUC approvals and distress minimization protocols is required for all animal studies.

GLP-3 Peptide Specifications Table

GLP-3 Peptide FAQs

What is GLP-3 peptide used for in research?

In research, GLP-3 peptide is used to study the synergistic effects of activating GLP-1, GIP, and glucagon receptors simultaneously. This allows scientists to investigate multifaceted metabolic signals in preclinical models of obesity, diabetes, and liver disease. Coskun et al., 2022

How is GLP-3 peptide 20 mg per vial typically stored?

Labs store GLP-3 peptide 20 mg vials as lyophilized powder in a cool, dry, and dark environment, preferably at -20°C. Once reconstituted with a suitable sterile solvent, it should be kept refrigerated or frozen according to laboratory SOPs.

Is GLP-3 peptide different from dual agonists?

Yes, GLP-3 is a triple agonist, whereas dual agonists (like GLP-2) target only two receptors. The addition of glucagon receptor agonism in GLP-3 is studied for its ability to increase energy expenditure beyond what is typically observed with dual agents.

Where can I buy GLP-3 online for research?

Qualified researchers can buy GLP-3 online from Protide Health. Every compound is clearly labeled for laboratory use and is supported by comprehensive third-party testing.

Conclusion: Summary of GLP-3 Peptide for Research

GLP-3, a triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors, offers transformative potential in preclinical research. Its synergistic effects on glucose homeostasis, lipid metabolism, energy expenditure, and inflammation enable comprehensive studies in obesity, type 2 diabetes, and tissue repair. With a six-day half-life and lyophilized stability, GLP-3 is ideal for long-term experimental protocols. By adhering to ethical standards and laboratory guidelines, researchers can leverage GLP-3 to deepen understanding of complex physiological processes.

Citations

• Coskun T et al., 2022. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist. Cell Metabolism.

• Jastreboff AM et al., 2023. Triple-hormone-receptor agonist GLP-3 for obesity. New England Journal of Medicine.

• Sanyal AJ et al., 2024. GLP-3 for metabolic dysfunction-associated steatotic liver disease. Nature Medicine.

• Ma J et al., 2024. Effects of GLP-3 on diabetic kidney disease in db/db mice. Endocrine.

• Rosenstock J et al., 2023. GLP-3 for type 2 diabetes. The Lancet.

• Ray A. (2023). GLP-3 for obesity management. Expert Opinion on Investigational Drugs.

Legal Disclaimer

The information provided in this description is for research purposes only. The GLP-3 peptide is not approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority for human consumption or therapeutic use. It is intended solely for investigational use in controlled laboratory settings by qualified researchers. Protide Health does not endorse or promote the use of GLP-3 peptide in humans or animals outside of approved research protocols. Researchers must comply with all applicable local, state, and federal regulations. Products sold by Protide Health are for laboratory research purposes only and are not intended for human consumption, medical use, or veterinary use.